NINGBO INNO PHARMCHEM CO.,LTD. recognizes the critical importance of robust clinical data in the pharmaceutical landscape. For targeted therapies like Capmatinib Hydrochloride, understanding the clinical efficacy is paramount for both healthcare professionals and the industry.

The cornerstone of evidence supporting Capmatinib Hydrochloride's use in treating Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutations is the GEOMETRY mono-1 trial. This pivotal phase II study was instrumental in demonstrating the drug's effectiveness and securing its regulatory approvals.

The GEOMETRY mono-1 trial was a multicenter, non-randomized, open-label study that enrolled patients with advanced or metastatic NSCLC, specifically those with confirmed MET exon 14 skipping mutations. The study evaluated the efficacy of Capmatinib Hydrochloride at a dose of 400 mg orally twice daily. Patients were treated until disease progression or unacceptable toxicity.

Key efficacy endpoints measured in the trial included the overall response rate (ORR), which is the percentage of patients who experienced a significant reduction in tumor size, and the duration of response (DOR). The results were highly encouraging:

  • Treatment-Naïve Patients: In the cohort of patients who had not received prior systemic therapy for their metastatic disease, Capmatinib Hydrochloride demonstrated an overall response rate of 68%.
  • Previously Treated Patients: For patients who had received at least one prior line of therapy, the ORR was 41%.
  • Duration of Response: The median duration of response was approximately 12.6 months for treatment-naïve patients and 9.7 months for previously treated patients, indicating sustained clinical benefit for many individuals.

These findings highlight the substantial impact Capmatinib Hydrochloride can have on patients with this specific genetic profile in NSCLC. The trial's success paved the way for its approval by regulatory agencies, positioning it as a vital therapeutic option.

At NINGBO INNO PHARMCHEM CO.,LTD., we provide the high-quality Capmatinib Hydrochloride required for such critical clinical applications. When exploring options to purchase Capmatinib Hydrochloride, understanding the data from trials like GEOMETRY mono-1 underscores its value and therapeutic potential. Our commitment to quality ensures that the APIs we supply are of the highest standard, supporting the development and availability of advanced cancer treatments.